Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The health economic implications of treatment with quetiapine: an audit oflong-term treatment for patients with chronic schizophrenia
Autore:
Lynch, J; Morrison, J; Graves, N; Meddis, D; Drummond, MF; Hellewell, JSE;
Indirizzi:
AstraZeneca, Macclesfield SK10 4TG, Cheshire, England AstraZeneca Macclesfield Cheshire England SK10 4TG 4TG, Cheshire, England St Lukes Hosp, Clonmel, Ireland St Lukes Hosp Clonmel IrelandSt Lukes Hosp, Clonmel, Ireland London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London, England LondonSch Hyg & Trop Med London England Hlth & Policy, London, England Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England Univ York York N Yorkshire England YO1 5DD YO1 5DD, N Yorkshire, England Trafford Gen Hosp, Manchester, Lancs, England Trafford Gen Hosp Manchester Lancs England p, Manchester, Lancs, England
Titolo Testata:
EUROPEAN PSYCHIATRY
fascicolo: 5, volume: 16, anno: 2001,
pagine: 307 - 312
SICI:
0924-9338(200108)16:5<307:THEIOT>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
COST-EFFECTIVENESS; ANTIPSYCHOTICS; RISPERIDONE; HALOPERIDOL; CLOZAPINE; SEROQUEL; PLACEBO; IMPACT; DRUGS; UK;
Keywords:
antipsychotic; audit; health economics; quetiapine; schizophrenia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Meddis, D AstraZeneca, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England AstraZeneca Alderley Pk Macclesfield Cheshire England SK10 4TG d
Citazione:
J. Lynch et al., "The health economic implications of treatment with quetiapine: an audit oflong-term treatment for patients with chronic schizophrenia", EUR PSYCHIA, 16(5), 2001, pp. 307-312

Abstract

This retrospective, case series audit assessed the clinical and health-economic impact of long-term treatment with quetiapine ('Seroquel'), a new atypical antipsychotic, in patients with chronic schizophrenia. The study design was of a case series format, comprising patients entered from one centreinto the open-label extension of a multicentre 6-week efficacy study. Twenty-one patients (15 male, six female; mean age 39 years) were studied, of whom 17 (81%) had been rated as 'partially responsive' to previous antipsychotics. Data on hospitalisations and information on symptoms were collected retrospectively for the 12 months before quetiapine treatment was initiatedand for the 12 months after. Quetiapine was eff effective in reducing psychotic symptoms with mean BPRSscores reducing significantly, from 38 to 21 (P < 0.005). Motor function was also significantly improved with mean Simpson scale scores reducing from15 to 12 (P < 0.005). Average inpatient days were reduced by 11% in year two (97 compared with 109 days) while the overall costs of treatment, including drug costs, fell by 5% (I pound 220,843 to I pound 19,827). Four patients had been hospitalised for longer than 5 years before starting quetiapine; these chronically institutionalised patients remained in hospital, despite improved clinical outcomes (mean BPRS scores after treatment of 34, compared with 43 before), for the full 12 months of quetiapine treatment. Were the data from this audit to be re-analysed excluding these four patients then average inpatient days would have been reduced by 33% (45 to 30 days) andoverall cost of treatment by 19% (I pound 8617 to I pound 7011). This audit suggests that treatment with quetiapine over this 1-year periodwas associated with both clinical improvements and a decreased usage of inpatient services. The reduction in hospitalisation costs would appear to compensate for the increased cost of drug treatment. Significantly, potentialsavings appear to be greatest for those patients with a 'revolving door' pattern of repeated readmission. (C) 2001 Editions scientifiques et medicales Elsevier SAS.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 21:47:51